摘要
Abstract
OBJECTIVE:To observe the clinical efficacy and safety of recombinant tumor necrosis factor receptor (rhTN-TR)-Fc fusion protein combined with Yinxie granules for moderate and severe vulgaris psoriasis.METHODS:62 patients with moderate and severe vulgaris psoriasis were randomly divided into trial group and control group; trial group was given rhTNTR-Fc fusion protein 25 mg,twice a week,and Yinxie granules 6 g,tid.Control group was given rhTNTR-Fc fusion protein 25 mg,twice a week.Treatment course of 2 groups lasted for 12 weeks.Psoriasis area and severity index (PASI) of trial group was improved nu 90％ (PASI 90) 12 weeks later,and then they were given Yinxie granules 6 g,bid for consecutive 8 weeks.Therapeutic efficacy of 12-week treatment,the recurrence time and rate of PASI 90 patients during 2 years were compared between 2 groups.RE-SULTS:30 patients of trial group and 29 patients of control group finished the 12-week course of treatment.PASI 50,PASI 75 and PASI 90 was achieved by 96.7％,83.3％,60.6％ of patients in treatment group,and by 89.7％,82.8％,55.2％ of patients in control group,respectively.There was no statistical significance (P＞0.05).6 PASI 90 patients in trial group (33.33％) and 8 in control group (50.0％) suffered from psoriasis again during followed-up of 2 years; there was no statistical significance between 2 groups (P＞0.05),but recurrence time of trial group had delayed (P＜0.05).No severe ADR were observed in 2 groups,and there was no statistical significance in the incidence ofADR (P＞0.05).CONCLUSIONS:Therapeutic efficacy and ADR of rhTN-TR-Fe fusion protein combined with Yinxie granules is similar to rhTNTR-Fc fusion protein alone in the treatment of moderate and severe vulgaris psoriasis.However,combination therapy decreases the recurrence rate and delays the recurrence.关键词
银屑病/重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/银屑颗粒/疗效/安全性/复发率Key words
Psoriasis/Recombinant tumor necrosis factor receptor-Fc fusion protein/Yinxie granules/Therapeutic efficacy/Safety/Recurrence rate分类
医药卫生
